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B cells have been implicated in transplant rejection via antibody-mediated mecha-
nisms and more recently by presenting donor antigens to T cells. We have shown in 
patients with chronic antibody-mediated rejection that B cells control the indirect T 
cell alloresponses. To understand more about the role of B cells as antigen-presenting 
cells for CD4+ T cell with indirect allospecificity, B cells were depleted in C57BL/6 
mice, using an anti-CD20 antibody, prior to receiving MHC class I–mismatched (Kd) 
skin. The absence of B cells at the time of transplantation prolonged skin graft sur-
vival. To study the mechanisms behind this observation, T cells with indirect allo-
specificity were transferred in mice receiving a Kd skin transplant. T cell proliferation 
was markedly inhibited in the absence of recipient B cells, suggesting that B cells 
contribute to indirect pathway sensitization. Furthermore, we have shown that a pos-
sible way in which B cells present alloantigens is via acquisition of MHC-peptide com-
plexes. Finally, we demonstrate that the addition of B cell depletion to the transfer 
of regulatory T cells (Tregs) with indirect alloresponse further prolonged skin graft 
survival. This study supports an important role for B cells in indirect T cell priming 
and further emphasizes the advantage of combination therapies in prolonging trans-
plant survival.
K E Y W O R D S
animal models: murine, antigen presentation/recognition, B cell biology, immune regulation, 
immunobiology, immunosuppression/immune modulation, translational research/science
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1  | INTRODUC TION
Solid organ transplantation is the best treatment available for 
organ failure; however, many transplants are lost within 12 years. 
The biggest single cause of transplant failure is immune-related 
injury.
T cell–mediated rejection is initiated when T cells are stimulated 
in response to graft alloantigens (alloAgs) via three major pathways 
of allorecognition. (1) The “direct pathway” where recipient T cells 
recognize intact donor major histocompatibility complex (MHC) 
molecules from donor antigen-presenting cells (APCs), and (2) the 
“indirect pathway” where presentation of donor alloAgs occurs after 
processing and presentation by host recipient APCs.1 In the third 
pathway of allorecognition, the “semi-direct,” recipient APCs ac-
quire intact donor MHC molecules and present to recipient T cells 
with direct allospecificity.2 We have recently demonstrated in a 
mouse model of skin transplant that the semi-direct pathway lasts 
for the entire duration of the life of the transplant, implying that 
the direct recognition of donor alloAgs plays a role not only early 
posttransplant but also at late time points posttransplant.3 Recently, 
Morelli et al and Marino et al have suggested that “cross-dressing” 
of recipient dendritic cells (DCs) with donor MHC molecules via 
the acquisition of extracellular vesicles (EVs), is the main contribu-
tor of priming of the direct alloresponse in skin graft rejection early 
posttransplant.4,5
The presence of antibodies (Abs) against HLA is in most cases a 
predictive marker of transplant failure, and the level of circulating Abs 
against donor antigens correlates with chronic Ab-mediated rejec-
tion.6,7 B cells are best known for their unique role as Ab-producing 
cells and Abs binding to the graft lead to the deterioration of the organ 
by Ab-mediated rejection mechanisms. Recent data have shown an 
additional role for recipient B cells, demonstrating that these cells can 
contribute to graft survival/rejection by presenting alloAgs to recipi-
ent T cells.8-10 As discussed later, we have shown that B cells specific 
for alloAgs are particularly efficient in amplifying T cell responses 
with indirect allospecificity.9 It is important to note that there is com-
pelling data from murine models suggesting that the antigen-pre-
senting functions of B cells, rather than antibody formation, are the 
primary reason why B cells are required for chronic rejection.11-14
Depletion of B cells has been applied in different murine mod-
els to improve transplant survival of MHC mismatched allografts. 
However, a diverse range of outcomes has been observed. In one 
study, B cell depletion did not alter the survival of fully mismatched 
kidney or heart allografts,8 whereas in other studies accelerated 
rejection was observed.15 The latter was hypothesized to be a 
consequence of depletion of IL-10–producing regulatory B cells 
(Bregs), which serve to suppress antigen-specific responses.16-20 
Furthermore, although some of the early experiments using deplet-
ing Abs suggested that B cells play an important role during T cell 
priming,21-23 further research using genetically modified mice defi-
cient in the B cell compartment produced conflicting results.14,24-29
In the clinical setting, several desensitization therapies aiming 
to target donor-specific antibody (DSA) levels in highly sensitized 
patients prior to transplantation are being tested, many of which 
involve B cell depletion. However, the differences in protocols, 
particularly the time of administration of the B cell–depleting 
drug, such as an anti-CD20 Ab rituximab, make the interpretation 
of the results difficult. One study has reported that rituximab in-
duction therapy may promote rather than inhibit acute cellular re-
jection in some patients,30 with one of the mechanisms suggested 
being depletion of B cells with regulatory function. In agreement 
with this idea, we have recently shown that operationally tolerant 
kidney-transplanted patients have “transitional” regulatory B cells 
that maintain high levels of IL-10 expression, further supporting 
the concept that some subpopulations of B cells might enhance 
graft survival.20
Furthermore, we have recently published that B cells make 
complex and dynamic contributions to the patterns of allore-
sponses seen in patients with chronic Ab-mediated rejection, in-
cluding patterns consistent with suppression of alloresponses in 
some. The data suggest that B cells, in addition to allo-Ab produc-
tion, are able to induce indirect T cell alloresponses by acting as 
APCs in some, but suppress indirect alloreactive T cell responses, 
at least in vitro, in others.9
In this study, the role of B cells as APCs for indirect CD4+ T cell 
alloresponses was examined in vivo. B cells were depleted (using an 
anti-CD20 Ab) in recipient mice receiving MHC class I–mismatched 
(Kd) skin grafts. We demonstrate that B cells contribute to the acti-
vation of CD4+ T cells with indirect alloresponses via acquisition of 
donor MHC molecules through the uptake of extracellular vesicles.
2  | MATERIAL AND METHODS
2.1 | Mice
Female BALB/c, C57BL/6 (B6), CBA/Ca mice were purchased from 
Harlan UK Ltd. (Biscester, Oxford, UK). TCR75Rag−/− (TCR75) and 
C57BL/6-Tg(Kd)Rpb (B6.Kd) were kindly provided by P. Bucy, IL-10–
deficient mice were kindly provided by W. Müller and B6.H2Kbm1, 
OT-1Rag−/−, and B6.mOVA were bred at Charles River, UK. All mice 
were maintained under sterile conditions (Biological Services Unit, 
New Hunt's House, King's College London).
2.2 | Flow cytometry
Cells were stained and analyzed as described elsewhere.31 (For more 
details see Supporting information.)
2.3 | B cell isolation
B cell purification was achieved using untouched CD43 conjugated 
Dynal beads (Thermofisher) following manufacturer's instructions. 
(For more details see SI.)
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2.4 | Skin transplantation
Donor tail skin grafts were performed and monitored as previ-
ously described.31 In some experiments, anti-CD8 antibody (clone 
YTS169, 250µg/injection/mouse) was injected intraperitoneally at 
day 1 before and day 1 after skin graft, and weekly thereafter. When 
described, B cells were depleted with 200µg of anti-CD20 (clone 
5D2, kindly provided by Genentech) by intravenous injection 7 days 
before skin transplantation.
2.5 | Generation of CD4+ CD25+ Treg line
Tregs with indirect specificity were created as outlined by Tsang 
et al.32 (For more details see SI.)
2.6 | CFSE labeling of DCs and isolation of EVs
Bone marrow (BM)–derived dendritic cells (BM-DCs) were gener-
ated as previously described.33 EVs were prepared as described in 
the SI.34 To measure the concentration and size of the particles iso-
lated, EVs were assessed on a NanoSight LM10 under a constant 
flow injection. Five videos of 30-second duration were recorded 
per sample. EVs isolated had a mean size of 159.2 nm and they 
expressed CD63 as assessed using an ExoELISA-ULTRA complete 
kit (CD63 detection), following the manufacturer's instructions 
(Systems Biosciences, California, USA). EV characterization is shown 
in Figure S1.
2.7 | DC, EV, and B cell co-culture and 
functional analysis
Recipient B cells were co-cultured for 18hours with carboxyfluo-
rescein succinimidyl ester (CFSE)–labeled donor DC derived EVs 
at a ratio of EVs derived from 100 DCs: 1 B cell. B cells were 
cultured alone as control. Following co-culture, B cells were in-
cubated with anti-CD16/32 Ab followed by anti-B220/CD45R 
APC conjugated Ab. Where described, B cells were incubated 
with anti-Kd APC-conjugated Ab. For functional analysis using 
EVs, recipient B6 B cells were co-cultured for 1hour with donor 
BALB/c or B6 DC-derived EVs as above before TCR75Rag−/− T 
cells were added at a 1:1 ratio of B-to-T cells. Cell culture super-
natants were removed on day 3 and IL-2 assessed by IL-2–specific 
ELISA (ThermoFisher).
2.8 | Statistical analysis
Graft survival data were analyzed using the Kaplan–Meier method, 
with the Wilcoxon rank test and the log-rank test used to verify the 
significance of difference between the groups (GraphPad Prism). 
Statistical analysis of other data was performed using the two-tailed 
Student's t test for unpaired samples with unequal variance.
3  | RESULTS
3.1 | B cell subpopulations in the spleen express 
high levels of CD20
To further understand the contribution of B cells as APCs in trans-
plant rejection, an anti-CD20 Ab was used to deplete B cells. CD20 
is first expressed in human pre-B cells in the BM, and its expres-
sion continues until B cells differentiate into plasma cells.35,36 In 
mouse, several reports have shown a similar CD20 expression 
pattern.37 In this study, we used a multi-parametric analysis to in-
vestigate the expression of CD20 by B cells during their develop-
ment.38,39 From pre-pro-B cell (B220+CD43+CD24lowBP-1neg) 
through pro-B cell (B220+CD43+CD24+BP-1neg) until pre-B-I cell 
(B220+CD43+CD24+BP-1+), stage CD20 was not expressed (Figure 1, 
Figure S2). However, CD20 was expressed at low densities at pre-B-
II cell stage (B220+CD43+CD24highBP-1+) and increased further dur-
ing B cell maturation (Figure S3). This is in line with previous reports, 
where it was shown that CD20 expression is parallel to the expres-
sion of immunoglobulin heavy chain.37
B cells egress from BM and migrate to secondary lymphoid organs. 
We analyzed the expression of CD20 on B cell subpopulations from 
spleen. Although all subpopulations analyzed expressed CD20, tran-
sitional 1 (T1) and T2 B cells (B220+CD21highsIgMhighCD93+CD23neg 
and CD23+, respectively), as well as marginal zone (MZ) and MZ pre-
cursors (B220+CD21lowsIgMhighCD23neg and CD23+, respectively) 
expressed CD20 at very high levels (Figure 1, Figure S3). Of note, 
MZ precursors are also described by some authors as T2 CD21low.38 
Although CD20 expression increases with B cell maturation, it has 
been reported that once B cells enter the B220high B cell pool, CD20 
expression decreases. This suggests that transitional B cells that ex-
press high levels of CD20 are recent BM emigrants, whereas mature 
B cells (eg, follicular B cells) express lower densities of CD20 com-
pared to T1, T2, and MZ B cells (Figure S3).
3.2 | Anti-CD20 antibody efficiently depletes 
mature B cells
After showing the distribution of CD20 in the different B cell sub-
populations in the BM and in the periphery, we injected B6 naïve 
mice intravenously with the anti-CD20 Abs, and the B cells popula-
tions were monitored. In our hands, the 5D2 clone administered in 
a single dose efficiently depleted B cells rapidly from blood, and by 
day 14, late pre-B cells to mature stages (Figure 2) could not be de-
tected in BM, whereas early precursors (ie, pre-pro-B cells to early 
pre-B cells) remained intact (Figure 2). These results are in line with 
those of previous reports using anti-CD20 Abs and consistent with 
CD20 expression patterns by BM B cells (Figure S2).
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In the spleen, CD20 is highly expressed by recent BM emi-
grants and transitional B cells and MZ precursor cells (Figure S3). 
Concurrently, these IgMhighCD24high B cell populations with the 
highest CD20 expression levels were the first cells to disappear from 
the spleen after treatment with anti-CD20 Abs (Figure S4, day 4). 
Mature B cells, such as follicular B cells, which express CD20 at a 
lower density than recent emigrants were not completely depleted 
until day 7 in spleen (Figure 3) and lymph nodes (LNs) (Figure S5). 
We confirmed that the depletion of B cells was long-lasting in the 
absence of inflammation, as after 2months B cells were still depleted 
(Figure S4, day 60).
3.3 | The absence of B cells at the time of skin 
transplant is necessary to induce prolongation of skin 
graft survival
After we confirmed that anti-CD20 Ab treatment depletes B cells, 
B6 mice transplanted with skin from a B6 mouse strain transgenic 
for Kd molecules (B6.Kd) received anti-CD20 Ab either 7days before 
(−d7) or 2days after (+d2) transplantation (Figure 4A). Furthermore, 
to focus on the antigen-presenting function of B cells for T cells 
with indirect allospecificity, recipient mice were injected with an 
anti-CD8 Ab at day −1 and +1, and then every week until mice 
completely rejected the skin graft, as published previously.31 Of 
note, anti-CD8 treatment depletes both CD8+ T cells and CD8+ DCs 
(Figure S6). Skin graft survival was prolonged for 8 days but only 
when anti-CD20 Ab was injected 7 days before transplantation 
but not 2days after (phosphate-buffered saline [PBS]; +d2 and –d7 
mean graft survival time were 11, 11.5, and 19 days, respectively) 
(Figure 4B).
Although anti-CD8 Ab alone did not prolong graft survival, an-
ti-CD20 prolonged skin graft survival only when combined with an-
ti-CD8 Abs (Figure S7 and Figure 4B). These results indicate that 
B cell depletion prolongs graft survival only after depletion of both 
CD8+ T cells and CD8+ DCs, strongly suggesting that B cells are 
presenting the Kd alloantigen to CD4+ T cells, most likely because 
graft rejection in this experimental setup is dependent on indirect 
allorecognition by CD4+ T cells.
A regulatory IL-10–producing B cell population has been re-
ported16-18 and if enriched in our experimental setting,15,40 could be 
responsible for the extended skin graft survival. Thus, IL-10–defi-
cient mice were treated with anti-CD8 Ab and anti-CD20 Ab using 
the same protocol applied to wild-type (WT) mice before transplant-
ing B6.Kd skins. Skin graft survival was extended in IL-10–deficient 
mice to an extent similar to that seen in WT mice (Figure S8), sug-
gesting that prolonged survival seen in association with anti-CD20 
was achieved independently of IL-10.
F I G U R E  1   CD20 expression on bone marrow and splenic B cell subsets in normal adult C57BL/6 mice. Bone marrow cells were gated 
on lymphocyte live cells. Then, B220+ cells were subdivided based on their CD43 expression. The earliest B lineage–committed stage 
(CD43+) was divided into Pre-Pro-B, Pro-B, late Pro-B/early Pre-B, and early Pre-B, whereas CD43− was divided into late-Pre-B, transitional, 
immature, early mature, and late mature B cells following Hardy's fractions, as detailed in Figure S1. Splenocytes were gated on lymphocyte 
live CD11bneg CD19+ cells. Following Allman and Pillai gating strategy, cells were gated based on their CD21 and IgM surface (sIgM) 
expression. sIgMhighCD21high cells were further divided into transitional 1 and transitional 2; sIgM+CD21+ were divided into follicular I and 
follicular II; sIgMhighCD21+ were divided into marginal zone (MZ) and MZ precursor cells, as detailed in Figure S2. Overimposed black dot 
plots showed CD20-expressing cells. Data are representative of 3 independent experiments
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3.4 | B cell depletion led to a delay in priming of 
CD4+ T cells with indirect allospecificity
To understand the mechanisms behind the increased skin survival 
following B cell depletion, and in the absence of CD8+ T cells and 
CD8+ DCs, T cells with indirect allospecificity obtained from a B6 
mouse strain transgenic for a T cell receptor (TCR)specific for Kd 
and restricted by Ab (TCR75)32,41 were adoptively transferred into 
B6 mice receiving a B6.Kd skin transplant following the injection of 
anti-CD8 Ab or anti-CD20 Ab alone or the 2 Abs in combination. 
CFSE-labeled TCR75 was injected at day−1. After 5 days, the mice 
were culled and CFSE dilution was evaluated (Figure 5A). TCR75 
cells proliferated significantly less in mice treated with anti-CD8 Ab 
or with anti-CD20 Ab alone compared to TCR75 cells from untreated 
mice (Figure 5B). These results, which support the accepted role of 
DCs in initiating the clonal expansion of CD4+ T cells with indirect 
F I G U R E  2   Anti-CD20 Ab treatment 
depletes mature B cells in bone marrow. 
Stained bone marrow cells were gated on 
lymphocyte live cells. Cells were gated as 
shown in Figure 1. Representative plots of 
B6 adult mice 14days after anti-CD20 Ab 
(200µg) intravenous injection are shown. 
The earliest B lineage–committed stage 
(CD43+) is not affected by anti-CD20 
treatment, although there is a shift toward 
more developed B cell stages (middle 
panel), whereas mature B cell stages are 
almost absent (right panel). Percentage 
of cells in BM from mice treated with 
anti-CD20 Ab is shown as individual mice 
and mean (lower panels). Experiments 
were performed with 4-5 mice per group. 



























































F I G U R E  3   Anti-CD20 Ab treatment depletes mature B cells in spleen. Stained splenocytes were gated on lymphocyte live CD11bneg cells. 
Cells were gated as shown in Figure 2. Representative histograms and plots of B6 adult untreated mice (top panels) and day 7 after anti-
CD20 Ab (200µg) intravenous injected mice (bottom panels). Percentage of CD19+cells in spleen from mice with and without anti-CD20 Ab 
treatment is shown as individual mice and mean (right panel). Experiments were performed with 4-5 mice per group. Data are representative 
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alloreactivity at this time point, demonstrate that B cells also play a 
crucial role as APCs for indirect presentation of alloAgs at early time 
points following skin transplantation.
3.5 | B cells are efficient in donor antigen capture
We have shown previously that graft rejection was attributed to 
the continuous acquisition of donor MHC class I by recipient DCs.31 
Recently Liu et al have shown that during skin transplantation, T cell 
priming and graft rejection are mediated via the release of donor 
DC–derived EVs, which are acquired by recipient conventional DCs.4 
In addition, Marino et al also observed that recipient B cells capture 
donor antigens via DC EVs.5 Based on this evidence and on our re-
sults so far we hypothesized that recipient B cells activate CD4+ T 
cells with indirect allospecificity by acquiring donor antigen through 
the uptake of EVs. One prediction of this is that we should find 
donor-derived Kd and I-Ad molecules on the surface of recipient B 
cells immediately after transplantation, and our data using congenic 
markers indicate that a proportion of recipient B cells from both 
spleen and draining lymph node, purified 4 days posttransplant, did 
express surface Kd and I-Ad (Figure S9).
We further confirmed in vitro that purified B cells can acquire 
MHC class I and II molecules from BM-DCs (Figure S10). To prove 
that MHC transfer from donor DCs to recipient B cells could be medi-
ated via EVs, purified B6 B cells were co-cultured with CFSE-labeled 
BM-DC EVs derived from BALB/c mice. As shown in Figure 6A, B 
cells became CFSE positive after co-culture, demonstrating that 
B cells were capable of acquiring CFSE-labelled DC-derived EVs 
and subsequently express acquired Kd molecules on their surface 
(Figure 6B). The acquisition of CFSE by B cells suggests that the EVs 
are fusing with the B cell membrane and then the donor MHC class I 
is processed and presented in the context of MHC class II, as shown 
previously to be one of the mechanisms of EV acquisition.42-45 
Furthermore, by culturing purified B cells B6 (H-2b) and CBA (H-2k) 
with BALB/c (H-2d) DC-derived EVs, we were able to detect intact 
MHC class I (Kd) (Figure S11A) and MHC class II (I-Ad) (Figure S11B) 
on the surface of recipient B cells, suggesting an alternative way that 
the donor MHC peptide complex is presented without need of fur-
ther processing and presentation.42-45
Next we addressed whether T cells with indirect allospecificity 
could be activated by recipient B cells following acquisition, process-
ing, and presentation of donor EVs bearing Kd molecules in the con-
text of recipient I-Ab molecules. To evaluate this, TCR75 T cells were 
used. Only B6 B cells co-cultured with BALB/c-derived EVs induced 
the activation of the TCR75 T cells, as measured by the release of 
IL-2, suggesting that the transferred MHC molecules were being in-
ternalized, processed, and loaded onto recipient I-Ab to drive indi-
rect CD4+ T cell responses (Figure 7A).
Asking a similar question, we investigated whether MHC class 
II–peptide complexes can be transferred from BM-DC EVs to B cells. 
To this end, EVs were isolated from B6.Kd BM-DCs and added to 
CBA (H-2k)–derived B cells prior to co-culture with TCR75 T cells. 
We observed that CBA B cells were able to activate TCR75 T cells 
F I G U R E  4   Anti-CD20 Ab treatment 
prolonged skin graft survival only 
when B cell depletion is achieved 
before transplantation. B6 mice were 
injected intravenously with anti-CD20 
Ab (200µg) 7days before or 2days after 
receiving dorsal B6.Kd skin transplant 
(day 0). Controls received PBS. Anti-CD8 
depleting Ab was administered at day −1 
and day +1, and every 7days thereafter. 
Skin survival was monitored daily. (A) 
Experimental design (B) plots show 
cumulative data of skin graft survival from 
3 independent experiments (n = 5-6/
group for each experiment). Statistics are 
calculated by log-rank (Mantel-Cox) test 
with Bonferroni correction for multiple 
comparisons. *** P < .001
-7 0 +8 days
B6.Kd skin
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following co-culture with B6.Kd DC–derived EVs but not with B6 
DC–derived EVs (Figure 7B). This suggests that intact class II (I-Ab) 
molecules presenting Kd peptide were transferred onto CBA B cells.
Altogether these results demonstrate that recipient B cells can 
acquire both intact MHC class I molecules and MHC class II mole-
cules containing class I–derived peptides via EV transfer, and that 
both can activate T cells with indirect specificity, the first requiring 
re-cycling of the newly acquired, EV-transferred membrane MHC 
class I via the endogenous MHC class II antigen processing pathway 
for presentation onto MHC class II, but the second not. Therefore 
these data support our hypothesis that B cells can acquire intact 
MHC via EV transfer to efficiently stimulate CD4+ T cells recognizing 
alloantigen in a self-MHC class II–restricted manner.
3.6 | Antigen-specific Tregs synergize with B cell 
depletion for skin graft survival prolongation
Having shown that B cells contribute to priming of T cells with in-
direct allospecificity and that Tregs have been shown previously to 
increase skin transplant survival in this skin transplantation model 
by controlling the indirect CD4+ T cell responses, we hypothesized 
that B cell depletion might synergistically prolong the graft survival 
induced by administration of Tregs with indirect allospecificity. We 
tested this by depleting B cells at day −7 and injecting Tregs with 
indirect allospecificity one day before transplantation as previously 
published32 (Figure 8A). As shown in Figure 8B, although either anti-
CD20 Ab treatment or the adoptive transfer of Tregs alone improved 
skin graft survival to a similar extent, for 9-11days beyond controls 
to a maximum of 31days, when the two therapies were combined, 
skin grafts survived up to 41days, demonstrating a synergistic ef-
fect. This result further emphasizes the advantage of combined 
therapies in transplantation to promote graft survival.
4  | DISCUSSION
In this study we have investigated the contribution of B cells in skin 
graft transplant survival/rejection. Uchida J et al observed that the 
effectiveness of anti-CD20 Abs to deplete B cells in vivo closely cor-
related with the subtype. The most efficient depletion was achieved 
by using immunoglobulin G isotype 2a (IgG2a), through a mechanism 
involving both Fc-γ receptor and macrophages.46 In this study we 
used a murine version of rituximab to deplete B cells, the monoclonal 
IgG2a anti-CD20 Ab, clone 5D2, which mediates cellular phagocyto-
sis of circulating B cells in the liver.47 The anti-CD8–depleting Ab was 
administered to prevent the CD8+ T cell direct alloresponse to donor 
Kd, but by also depleting the major population of lymphoid resident 
DC, it allowed us to assess the importance of B cells as APCs to prime 
CD4+ T cell indirect alloresponse in the absence of CD8+ DCs. Of 
F I G U R E  5   B cell depletion delays 
CD4+ T cells indirect alloresponses. B6 
mice (CD90.2) were injected intravenously 
with anti-CD20 Ab (200µg) 7days before 
receiving a dorsal B6.Kd skin transplant 
(day 0). Anti-CD8 depleting Ab was 
administered at day −1 and day +1 to mice 
that have received or not anti-CD20 Ab. 
Congenic (CD90.1) CFSE-labeled TCR75 
cells were adoptively transferred at early 
and late time points as indicated in the 
experimental design (A). Proliferation 
by CFSE dilution of CD90.1+ cells of 2 
independent experiment from pooled 
draining lymph node and spleens (n = 4-5/
group for each experiment) was analyzed 
by flow cytometry (B). *P < .05, **P < .01
A
B
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note, the removal of DCs alone did not affect the survival time, sug-
gesting that in their absence, the B cells can substitute effectively to 
prime the indirect alloresponse. The timing of administration of the 
anti-CD20 Ab was critical. Administration 2 days after transplanta-
tion had no impact on survival, whereas in mice transplanted 7 days 
after B cell depletion, when B cells are highly depleted in all immuno-
logical compartments, skin graft survival was significantly prolonged. 
These results indicate that B cell priming of T cells with indirect al-
lospecificity occurs in the immediate posttransplant period, and is 
further supported by experiments using adoptive transfer of CD4+ 
T cells with indirect specificity, which underwent significant clonal 
expansion within 4 days posttransplant, but only when B cells were 
present. We also present data to support the recently proposed idea 
that following skin transplantation, acquisition of donor MHC mol-
ecules onto the B cell membrane via EV transfer (“cross-dressing”) is 
a mechanism by which recipient B cells can acquire donor antigen for 
uptake, processing, and loading into recipient class II MHC capable 
of priming T cells with indirect allospecificity.
Recently, the dogma suggesting that allograft responses are 
driven by trafficking donor passenger leukocytes has been chal-
lenged by two groups.4,5 Both groups have shown that direct T cell 
alloresponses were primed early following transplantation despite 
very few donor DCs4 or no donor leukocytes5 trafficking from the 
graft, and that significant numbers of recipient cells expressed 
donor MHC molecules. In fact Marino et al identified that around 
60%-70% CD11c+ recipient DCs and 10%-15% recipient CD20+ B 
cells were “cross-dressed” by day 7 following skin transplantation. 
In addition, Lui et al have shown that “cross-dressing” of recipient 
cDCs with donor MHC molecules is the main contributor of priming 
direct alloresponses early postheart transplant leading to rejection. 
Both groups attributed cross-dressing to the release and acquisi-
tion of donor EVs, although the origin of the EVs is still not known. 
Martino et al found expression of CD3, CD20, and CD11c on the 
EVs, suggesting their origins to be T, B, and DCs, respectively, 
whereas Lui et al suggest that the donor EVs were derived from 
donor DCs. Marino et al showed that EV-derived B6 MHC mole-
cules on BALB/c splenocytes could activate alloreactive T cells both 
in vitro and in vivo, although they did not assess whether this was 
due to activation of T cells with direct or indirect allospecificity. Our 
results highlight that B cells efficiently acquired, via EV transfer, 
donor MHC molecules that are expressed by DC and that these B 
cells were functional and could activate CD4+ T cells with indirect 
allospecificity; in vivo, this was unveiled in the absence of CD8+ DC. 
Although the level of MHC transferred may seem low, the levels 
were similar to those observed previously between DCs.48 Based 
on the evidence that B cells contribute to the priming of T cells with 
F I G U R E  6   B cells acquire MHC 
molecules from DCs via EV transfer. EVs 
were isolated from CFSE-labeled BALB/c 
DCs and co-cultured with B6 B cells. 
Controls were non–EV-treated B cells. 
B cell acquisition of EVs was assessed 
by flow cytometry. Dot plots show 
representative data of 1 of 3 independent 
experiments, and the cumulative data are 
shown in the bar chart (right) (A). Levels 
of MHC class I Kd on B cells following 
exposure to BALB/c EVs were assessed by 
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indirect allospecificity, we provide evidence that B cell depletion 
generated a permissive environment for the enhanced function of 
alloAg-specific Tregs, leading to increased transplant survival.
Our in vitro data indicate that the antigen specificity of the B cell 
is not relevant to the uptake of MHC from EV onto the B cell surface, 
or the ability of the B cell to process and present these newly ac-
quired membrane MHC via the class II pathway. However, our work 
does not address the relevance of the antigen specificity of the B cells 
that acquire MHC from EV in vivo postskin transplantation. Given 
that antigen-specific B cells are highly likely to bind the donor-derived 
MHC-expressing EVs with high affinity, and process the allogeneic 
MHC bound to the B cell receptor for presentation on MHC class II 
with extremely high efficiency, we speculate that in vivo, the relevant 
B cells involved in our model are probably Kd specific.
Transplantation across histocompatibility barriers results in 
acute rejection in the absence of immunosuppression. Nonselective 
immunosuppressive agents leave patients vulnerable to infections 
and cancers.49 Thus, a major effort in the field of transplantation 
immunology is to generate therapies able to induce donor-specific 
tolerance leaving intact the rest of the immune system. B cells are 
key players in inducing adaptive immune responses. Further to their 
role as the precursors of Ab-producing plasma cells, B cells play an 
important role as APCs in T cell responses. Several studies have 
established the requirement of B cells for the generation of CD4+ 
memory T cells in most antigenic contexts (eg, viral, autoimmu-
nity),50-52 and although DCs are key in the initiation of CD4+ T cell 
activation, B cells are required for their subsequent activation.29,53
In the clinic, rituximab is currently being added to immunosup-
pressive regimens, mostly when transplanting across blood-group 
antibody barriers, however, with no real understanding of whether 
it gives benefit above other depleting agents. Anti-CD20 Abs 
have no effect on plasma cells, since they do not express CD20; 
therefore, rituximab does not immediately decrease the level of 
circulating anti-donor Abs. However, it is important to highlight 
that recent trials with multiple sclerosis patients have shown that 
B cell depletion had a beneficial effect, but the clinical response 
was not associated with reduction in Ab levels.54-57 Similarly, in 
type 1 diabetes where auto-Abs do not play a key role, B cell de-
pletion improves outcome. This suggests the importance of B cells 
as APCs and their role in sustaining CD4+ effector and memory 
responses. Furthermore, B cell depletion in mouse models of au-
toimmune diseases significantly reduced CD4+ T cell responses to 
foreign and self-antigens, whereas CD8+ T cell reactivity remains 
unaffected.21 Recently, we have shown that ex vivo B cell deple-
tion in some patients with chronic Ab-mediated rejection led to 
reduced indirect T cell alloresponses in a recall assay, suggesting 
their role as APCs.9 However, in another group of patients, pre-
sented in the same study, ex vivo B cell depletion led to increased 
responses, suggesting they also are able to suppress indirect T 
cell responses.9 Thus, understanding the mechanism governing 
graft rejection at different stages and the cellular components 
that play a key role is paramount for the rationale in generating 
new immunotherapies. Here we demonstrated that injecting an-
ti-CD20 Ab 7 days before skin transplant so that B cells were ab-
sent at the time of transplantation (in the absence of DCs), led 
to increased transplant survival and prevented the proliferation 
of adoptively transferred T cells with indirect allospecificity, both 
demonstrating the contribution of B cells at inducing the indirect 
alloresponses that underpin acute rejection in this model system. 
Mechanistically, we were able to confirm that our results were not 
due to the preferential survival of IL-10–producing regulatory B 
cell populations that control immune responses against the graft, 
since the same results were obtained in IL-10–deficient mice. 
Although we cannot completely rule out that Bregs play a role in 
the early phase of rejection, we did not observe any difference 
under our experimental settings.
It has also been reported that rituximab treatment could pro-
mote the expansion of Treg populations.58,59 Tregs are key play-
ers in maintaining immune homeostasis and tolerance to self. 
Currently, the clinical use of Tregs in the clinic for transplanted 
patients has being explored.60-63 Furthermore, Tregs can control 
F I G U R E  7   Transferred EV-derived MHC drives indirect CD4+ T 
cell responses. EVs derived from BALB/s (A) or B6.Kd (B)–derived 
DCs were added to B6 (A) or CBA (B) B cells before co-culturing 
with TCR75 cells. Control B6 EVs were included. IL-2 was assessed 
after 3 days using an IL-2 ELISA. Data represent 1 of 3 experiments 
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B cell responses by constraining T cell help.64-66 Here we demon-
strated that by combining B cell depletion with the transfer of 
Tregs with indirect allospecificity, a synergistic effect is observed. 
It is important to highlight that B cells are important players during 
the early phase of graft rejection and that although CD4+ T cells 
responses are impaired in the absence of B cells and skin graft 
survival is prolonged, the graft is ultimately rejected. However, we 
showed here that there is room for improvement of current ther-
apies and understanding the mechanisms behind graft rejection 
and that survival is important to combined therapies in a rational 
manner.
Altogether our results further emphasize an important contribu-
tion by B cells as APCs in T cell priming, and highlight the potential 
value of B cell depletion as adjunctive immunosuppression.
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